Table 2.
Trends in proportion of non-screened breast cancers in all breast cancers diagnosed during 1995–2011 among women in England
| Segment | Start year | End year | APC (95% CI) | p parallelism | |||
|---|---|---|---|---|---|---|---|
| n | (%) | n | (%) | ||||
| All | 1995–2007 | 4,665 | (62.7) | 7,907 | (43.0) | −3.5 (−4.2 to −2.8) | <0.001 |
| 2007–2011 | 7,907 | (43.0) | 12,991 | (52.4) | 5.6 (2.2 to 9.1) | ||
| Race | |||||||
| Black | 1995–2011 | <15 | (72.7) | 100 | (62.9) | −1.8 (−3.3 to −0.3) | reference |
| Other | 1995–2008 | 3,451 | (63.1) | 2,259 | (40.0) | −4.1 (−6.6 to −1.5) | 0.879 |
| 2008–2011 | 2,259 | (40.0) | 4,644 | (53.2) | 12.9 (−4.2 to 33.0) | ||
| White | 1995–2007 | 1,202 | (59.0) | 5,658 | (45.8) | −3.5 (−5.5 to −1.4) | 0.783 |
| 2007–2011 | 5,658 | (45.8) | 8,247 | (51.8) | 4.2 (−0.8 to 9.5) | ||
| Histology | |||||||
| IDC | 1995–2007 | 2,985 | (60.2) | 5,894 | (42.7) | −3.3 (−4.1 to −2.5) | 0.998 |
| 2007–2011 | 5,894 | (42.7) | 9,651 | (51.6) | 5.3 (1.7 to 9.0) | ||
| ILC | 1995–2007 | 532 | (63.1) | 938 | (43.2) | −3.3 (−3.9 to −2.8) | reference |
| 2007–2011 | 938 | (43.2) | 1,731 | (54.5) | 5.4 (2.9 to 8.0) | ||
| MDLC | 1995–2007 | 25 | (30.5) | 299 | (35.1) | −3.6 (−5.9 to −1.3) | 0.176 |
| 2007–2011 | 299 | (35.1) | 319 | (47.6) | 9.6 (0.9 to 18.9) | ||
| Other | 1995–2007 | 1,135 | (72.2) | 924 | (51.0) | −4.1 (−4.9 to −3.3) | 0.005 |
| 2007–2011 | 924 | (51.0) | 1,483 | (57.9) | 2.9 (1.0 to 4.8) | ||
| Staging | |||||||
| Stage 1 | 1995–2008 | 562 | (49.1) | 1,490 | (27.1) | −5.2 (−6.6 to −3.7) | reference |
| 2008–2011 | 1,490 | (27.1) | 2,745 | (31.4) | 5.6 (−4.9 to 17.3) | ||
| Stage 2 | 1995–2007 | 945 | (73.3) | 1,798 | (54.4) | −3.1 (−4.1 to −2.1) | 0.024 |
| 2007–2011 | 1,798 | (54.4) | 3,321 | (59.5) | 4.1 (−0.4 to 8.8) | ||
| Stage 3 | 1995–2011 | 122 | (88.6) | 852 | (70.1) | −1.8 (−2.5 to −1.1) | 0.003 |
| Stage 4 | 1995–2011 | 70 | (90.1) | 701 | (77.9) | −1.0 (−1.3 to −0.7) | 0.048 |
| Grade | |||||||
| Grade 1 | 1995–2007 | 581 | (42.0) | 857 | (24.9) | −5.1 (−6.2 to −3.9) | reference |
| 2007–2011 | 857 | (24.9) | 1,332 | (31.6) | 7.0 (1.1 to 13.2) | ||
| Grade 2 | 1995–2007 | 1,520 | (59.8) | 3,362 | (38.4) | −4.3 (−5.1 to −3.5) | 0.018 |
| 2007–2011 | 3,362 | (38.4) | 5,916 | (48.7) | 6.4 (2.9 to 10.1) | ||
| Grade 3 | 1995–2008 | 1,235 | (73.9) | 3,311 | (58.5) | −2.1 (−2.6 to −1.6) | 0.001 |
| 2008–2011 | 3,311 | (58.5) | 4,935 | (66.7) | 5.7 (1.9 to 9.5) | ||
APC, annual percentage change; CI, confidence intervals; IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MDLC, mixed ductal and lobular carcinoma; p, p-values of parallelism test for the within group differences (< 0.05 indicates different slopes/trends compared with the reference).